Citations |
- Kameshima H et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci. 102, 1181-7 (2011)(PMID:21371173)
- Miyazaki A et al., Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci. 102, 324-9 (2011)(PMID:21143701)
- Shima H et al. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. Cancer Immunol Immunother. 67, 1603-1609 (2018)(PMID:30069687)
- Shibayama M et al. Implication of chemo-resistant memory T cells for immune surveillance in patients with sarcoma receiving chemotherapy. Cancer Sci. 108, 1739-1745 (2017)(PMID:28699227)
- Watanabe K et al. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci. 110, 40-51 (2019)(PMID:30375705)
- Kurosawa N et al. High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A*A24 and its application in a bispecific T-cell engager. Sci Rep. 9, 9827 (2019)(PMID:31285464)
|